Q4 2021 Results slide image

Q4 2021 Results

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Hematology 126 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation